Company: SCLXW
Filing Date: 2025-12-16
Form Type: S-1
Source: 0001193125-25-319720
Chunk: 222

Company: Scilex Holding Co
Filing Date: 2025-12-16
Form: S-1
Chunk 222
---
       (195 | ) |
| Total ELYXYB                            |     |                         | 2,022 |     |   |  2,551 |     |   |       (529 | ) |
| Total Research and Development Expenses |     | $                       | 9,641 |     | $ | 12,746 |     | $ |     (3,105 | ) |

**Research and development expenses for the years ended December 31, 2024 and 2023 were $9.6 million and $12.7 million, respectively. The $3.1 million decrease was primarily attributed to reduced costs of SP-103due to the completion of the Phase 2 clinical study and reduced development costs of SP-104. Selling, General and Administrative Expenses Selling, general and administrative expenses for the years ended December 31, 2024 and 2023 were $119.0 million and $119.6 million, respectively. The decrease of approximately $0.6 million was primarily due to a $10.1 million decrease in legal fees, a $1.6 million decrease in insurance costs, a $0.4 million decrease in 147

advisory and financing expenses and a $0.2 million decrease as a result of a $1.4 million decrease related to allowance for credit losses that was made in March 2023 for the receivable from Sorrento offset by a $1.2 million increase related to allowances for expected credit losses on accounts receivable, partially offset by a $5.5 million increase in rebate expense related to future shipments of the Additional Product under the Satisfaction Agreement, a $2.9 million increase in contracted services, a $1.7 million increase in personnel expense due to increase in headcount and a merit increase starting January 2024, a $0.5 million increase in travel expenses, a $0.1 million increase in marketing expenses and a $1.0 million increase in other expenses.

Intangible Amortization Expense

Intangible amortization expense for the years ended December 31, 2024 and 2023 was $4.0 million and $4.1 million, respectively. The decrease of $0.1 million is related to the full amortization of the assembled workforce intangible asset (see Note 6 titled “Goodwill and Intangible Assets” to our consolidated financial statements included elsewhere in this prospectus for additional information).

Legal Settlements

Legal settlements for the years ended December 31,